<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553928</url>
  </required_header>
  <id_info>
    <org_study_id>14603A</org_study_id>
    <nct_id>NCT02553928</nct_id>
  </id_info>
  <brief_title>Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and Mini Mental State Examination (MMSE)Range 5 - 18</brief_title>
  <official_title>Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and MMSE Range 5 - 18</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the safety and tolerability of a 20 mg once daily dose of memantine compared
      with 10 mg given twice daily in patients with dementia of Alzheimer's type and MMSE range
      5-18.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute values and changes from baseline in safety variables (Adverse events, clinical safety laboratory tests, vital signs, weight, and ECG)</measure>
    <time_frame>baseline to week 16 (end of study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global clinical impression in ADCS - CGIC score</measure>
    <time_frame>Change from baseline to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Alzheimer Dementia (AD)</condition>
  <arm_group>
    <arm_group_label>Memantine (once daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Memantine 20 mg once daily, tablets, orally AND Placebo tablets once daily, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Memantine (twice daily)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg given twice daily, tablets, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine (once daily)</intervention_name>
    <arm_group_label>Memantine (once daily)</arm_group_label>
    <other_name>Lu 00-800</other_name>
    <other_name>Ebixa ®</other_name>
    <other_name>Ebix ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine (twice daily)</intervention_name>
    <arm_group_label>Memantine (twice daily)</arm_group_label>
    <other_name>Lu 00-800</other_name>
    <other_name>Ebixa ®</other_name>
    <other_name>Ebix ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has a knowledgeable and reliable caregiver who will accompany the patient
             to all clinical visits during the study.

          -  The patient has a diagnosis of probable AD consistent with the National Institute of
             Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and
             Related Disorders Association (NINCDS-ADRDA) criteria.

          -  The patient has a Mini Mental State Examination (MMSE) score ≥ 5 and ≤ 18 at Screening
             visit

          -  The dose of Memantine has been stable at 20 mg once a day for at least 3 month prior
             to screening.

        Exclusion Criteria:

          -  The patient has a history of severe drug allergy or hypersensitivity, or known
             hypersensitivity to the IMP or its excipients.

          -  The patient has one or more of the following conditions: Evidence and/or history of
             any clinically significant neurodegenerative disease or other serious neurological
             disorders other than Alzheimer's disease including, but not limited to, Lewy body
             dementia, Fronto-Temporal dementia, Parkinson's disease, Huntington's disease, major
             cortical stroke, Multiple Sclerosis, major head trauma and primary or secondary
             cerebral neoplasm.

          -  The patient has a modified Hachinski ischemia score greater than 4 at the screening
             visit.

          -  The patient has any current psychiatric disorder or Axis I disorder (DSM-IV-TR™
             criteria), established as the primary diagnosis, other than AD

          -  The patient is currently receiving treatment with an unstable dose of acetyl
             cholinesterase inhibitor

          -  The patients has clinical significant abnormal screening values ( vital signs,
             laboratory, ecg, B12.

        Other protocol defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CN002</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 10, 2017</submitted>
    <returned>November 16, 2017</returned>
    <submitted>February 22, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

